APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
-1.01%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$4.36B
AUM Growth
+$4.36B
(-3.3%)
Cap. Flow
+$173M
Cap. Flow
% of AUM
3.97%
Top 10 Holdings %
Top 10 Hldgs %
45.02%
Holding
102
New
10
Increased
31
Reduced
13
Closed
19
Top Buys
| 1 |
Eli Lilly
LLY
|
$198M |
| 2 |
argenx
ARGX
|
$150M |
| 3 |
SPDR S&P Biotech ETF
XBI
|
$107M |
| 4 |
Humana
HUM
|
$99.9M |
| 5 |
Johnson & Johnson
JNJ
|
$97M |
Top Sells
| 1 |
Merck
MRK
|
$194M |
| 2 |
Baxter International
BAX
|
$149M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$146M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$115M |
| 5 |
AbbVie
ABBV
|
$109M |
Sector Composition
| 1 | Healthcare | 95.35% |
| 2 | Financials | 0.54% |
| 3 | Technology | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
AstraZeneca
AZN
$248B
| $231M | 5.31% | 3,499,000 -201,000 | -5% | -$13.3M |
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $223M | 5.13% | 793,000 +247,400 | +45% | +$69.7M |
|
|
3
argenx
ARGX
$43.6B
| $217M | 4.98% | 572,500 +396,500 | +225% | +$150M |
|
4
Elevance Health
ELV
$71.8B
| $213M | 4.89% | 441,000 +41,600 | +10% | +$20.1M |
|
5
Avantor
AVTR
$9.18B
| $207M | 4.75% | 6,652,700 +984,400 | +17% | +$30.6M |
|
|
6
Eli Lilly
LLY
$657B
| $198M | 4.54% | +610,000 | New | +$198M |
|
|
7
Humana
HUM
$36.5B
| $193M | 4.43% | 412,300 +213,400 | +107% | +$99.9M |
|
8
United Therapeutics
UTHR
$13.8B
| $171M | 3.93% | 725,600 +6,654 | +0.9% | +$1.57M |
|
|
9
Johnson & Johnson
JNJ
$427B
| $160M | 3.67% | 900,200 +546,200 | +154% | +$97M |
|
|
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $148M | 3.4% | 1,856,900 +725,500 | +64% | +$57.9M |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $143M | 3.28% | 1,467,600 +307,600 | +27% | +$30M |
|
12
Arvinas
ARVN
$568M
| $141M | 3.24% | 3,355,623 +440,323 | +15% | +$18.5M |
|
|
13
SPDR S&P Biotech ETF
XBI
$5.07B
| $139M | 3.2% | 1,875,000 +1,435,000 | +326% | +$107M |
|
14
McKesson
MCK
$85.4B
| $127M | 2.91% | 388,800 +199,300 | +105% | +$65M |
|
15
UnitedHealth
UNH
$281B
| $124M | 2.86% | 242,200 -17,400 | -7% | -$8.94M |
|
|
16
AbbVie
ABBV
$372B
| $116M | 2.65% | 755,000 -711,100 | -49% | -$109M |
|
17
Syndax Pharmaceuticals
SNDX
$1.41B
| $105M | 2.41% | 5,450,000 +626,600 | +13% | +$12.1M |
|
|
CTLT
18
DELISTED
CATALENT, INC.
CTLT
| $102M | 2.35% | 955,000 +173,000 | +22% | +$18.6M |
|
19
Zentalis Pharmaceuticals
ZNTL
$122M
| $101M | 2.31% | 3,585,881 +408,882 | +13% | +$11.5M |
|
|
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
| $97.3M | 2.23% | 550,000 +450,000 | +450% | +$79.6M |
|
21
Boston Scientific
BSX
$156B
| $94.1M | 2.16% | 2,525,000 +1,328,900 | +111% | +$49.5M |
|
22
Biogen
BIIB
$19.4B
| $89.8M | 2.06% | 440,566 +75,566 | +21% | +$15.4M |
|
23
Ultragenyx Pharmaceutical
RARE
$2.89B
| $88.3M | 2.03% | 1,479,500 +610,500 | +70% | +$36.4M |
|
24
Acadia Healthcare
ACHC
$2.12B
| $70M | 1.61% | +1,035,000 | New | +$70M |
|
25
Intellia Therapeutics
NTLA
$1.22B
| $58.2M | 1.34% | 1,125,194 +735,119 | +188% | +$38M |
|